Article

Read about our clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor in patients with various solid tumors with known PI3Kα mutations.

We are pleased to announce that our new drug, TOS-358, has begun clinical trials for treating solid tumors with known PI3Kα mutations. TOS-358 is a first-in-class covalent PI3Kα inhibitor, which binds to and irreversibly inactivates the PI3Kα protein. The PI3Kα protein involves several important signaling pathways for cancer cell growth and survival. By inhibiting PI3Kα, TOS-358 may be able to kill cancer cells and prevent tumor growth.

The clinical trial of TOS-358 is currently in the dose-escalation phase. This means that we are gradually increasing the dose of TOS-358 given to patients to determine the maximum tolerated dose and assess the drug's safety and tolerability at different dose levels. The trial also evaluates the efficacy of TOS-358 in terms of tumor response rate and progression-free survival.

We recruit patients with various tumor types, including colorectal, gastric, breast, lung, and endometrial cancer. If you want to participate in the trial, don't hesitate to contact your doctor or us directly.

We are excited about the potential of TOS-358 to help patients with cancer, and we are committed to developing and delivering this important new drug to patients as quickly as possible.